Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

SNY, ABBV, RHHBY and NVS will announce Q4 results and regular pipeline and regulatory updates next week.

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

Now let’s return to the three factors that will influence biosimilar oncology drug uptake in Europe ... very closely at the evidence base for new cancer biosimilars reaching the market, and ...

which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.